Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2347463 | 0.89 | EPHX2 (0.49) | EPHX2ALDH1A1GAACA12CA1 | |
| SCHEMBL22919868 | 0.85 | EPHX2 (0.47) | EPHX2ALDH1A1GAACA12CA1 | |
| SCHEMBL31341992 | 0.85 | ALDH1A1 (0.56) | ALDH1A1GAACA12CA1CA9 | |
| SCHEMBL2072185 | 0.85 | ALDH1A1 (0.56) | ALDH1A1GAACA12CA1CA9 | |
| SCHEMBL29362736 | 0.83 | ALDH1A1 (0.51) | EPHX2ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14744283 | 0.83 | ALDH1A1 (0.51) | EPHX2ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL23118871 | 0.82 | EPHX2 (0.69) | EPHX2ALDH1A1GAACA12CA1 | |
| SCHEMBL29792603 | 0.82 | EPHX2 (0.69) | EPHX2ALDH1A1GAACA12CA1 | |
| SCHEMBL15168933 | 0.81 | EPHX2 (0.51) | EPHX2ALDH1A1GAACYP1A2CYP2C9 | |
| SCHEMBL30135043 | 0.81 | AAK1 (0.55) | CA12CA1CA9HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9750719-B2 | Tetrazole compounds as calcium channel blockers | Convergence Pharmaceuticals Limited (GB) | 2017-09-05 | — | — | US | disclosed |
| US-9750719-B2 | Tetrazole compounds as calcium channel blockers | Convergence Pharmaceuticals Limited (GB) | 2017-09-05 | — | — | US | disclosed |
| US-20160015687-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited (GB) | 2016-01-21 | — | — | US | disclosed |
| US-20160015687-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited (GB) | 2016-01-21 | — | — | US | disclosed |
| US-9115132-B2 | Tetrazole compounds as calcium channel blockers | Convergence Pharmaceuticals Limited (GB) | 2015-08-25 | — | — | US | disclosed |
| US-9115132-B2 | Tetrazole compounds as calcium channel blockers | Convergence Pharmaceuticals Limited (GB) | 2015-08-25 | — | — | US | disclosed |
| US-20130210796-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited | 2013-08-15 | — | — | US | disclosed |
| US-20130210796-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited | 2013-08-15 | — | — | US | disclosed |
| US-8067582-B2 | Fused heterocyclic compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100331324-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQIOBB COMPANY | 2010-12-30 | — | — | US | disclosed |
| WO-2009003077-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-31 | — | — | WO | disclosed |
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210796-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1I, CACNB2 | EPHX2 2950/4885ALDH1A1 2584/4885GAA 1370/4885 |
| US-20160015687-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1I, CACNB2 | EPHX2 2950/4885ALDH1A1 2584/4885GAA 1370/4885 |
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | EPHX2 1186/4885ALDH1A1 2454/4885GAA 2875/4885 |
| US-20100331324-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | NR5A1, AR, ESRRA | EPHX2 2234/4885ALDH1A1 967/4885GAA 3164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.